ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants IRBM access to ERS’ CRISPR/Cas9 patent portfolio.
Opinion | The Trouble With Upcoding Extends Far Beyond Ethics
Devereaux is a retired board-certified family physician. After a long day in my primary care practice in rural southwest Virginia, I still had one more
November 12, 2024